Doxycycline post-exposure prophylaxis: Weekly versus event-driven Intake for STI prevention among MSM and TGW taking PrEP (Doxy-WISE study)

Conditions

Sexually Transmitted Infections

Brief summary

Incidence rate ratio of NG, CT, and TP infections in the W-DoxyPEP vs ED-DoxyPEP arms

Detailed description

Rate ratio of tetracyclines, macrolides, cephalosporins, and penicillins in the W-DoxyPEP vs ED-DoxyPEP arms, MIC distribution (doxycycline/cefixime/ciprofloxacin) of commensal Neisseria spp., oral streptococci and E. coli in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of symptomatic NG infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of symptomatic CT infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of symptomatic TP infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of all NG infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of all CT infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of all TP infections in the W-DoxyPEP vs ED-DoxyPEP arms, Tetracycline MIC distribution of NG isolates in the W-DoxyPEP vs ED-DoxyPEP arms, participants' perception/experience, preference, and acceptability in using doxyPEP, Cost of integrating W-DoxyPEP vs ED-DoxyPEP in routine HIV-PrEP follow-up, if the strategy is proved to be effective, incremental cost per STI avoided/Quality of life Adjusted Life Years (QALY) gained

Related papers

No related papers found yet.

Interventions

DRUGDoxycycline Sandoz 100 mg tabletten

DRUGDoxycycline EG 200 mg Tabletten

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence rate ratio of NG, CT, and TP infections in the W-DoxyPEP vs ED-DoxyPEP arms	—

Secondary

Measure	Time frame
Rate ratio of tetracyclines, macrolides, cephalosporins, and penicillins in the W-DoxyPEP vs ED-DoxyPEP arms, MIC distribution (doxycycline/cefixime/ciprofloxacin) of commensal Neisseria spp., oral streptococci and E. coli in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of symptomatic NG infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of symptomatic CT infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of symptomatic TP infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of all NG infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of all CT infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of all TP infections in the W-DoxyPEP vs ED-DoxyPEP arms, Tetracycline MIC distribution of NG isolates in the W-DoxyPEP vs ED-DoxyPEP arms, participants' perception/experience, preference, and acceptability in using doxyPEP, Cost of integrating W-DoxyPEP vs ED-DoxyPEP in routine HIV-PrEP follow-up,	—

Measure

Time frame

Rate ratio of tetracyclines, macrolides, cephalosporins, and penicillins in the W-DoxyPEP vs ED-DoxyPEP arms, MIC distribution (doxycycline/cefixime/ciprofloxacin) of commensal Neisseria spp., oral streptococci and E. coli in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of symptomatic NG infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of symptomatic CT infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of symptomatic TP infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of all NG infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of all CT infections in the W-DoxyPEP vs ED-DoxyPEP arms, Incidence rate ratio of all TP infections in the W-DoxyPEP vs ED-DoxyPEP arms, Tetracycline MIC distribution of NG isolates in the W-DoxyPEP vs ED-DoxyPEP arms, participants' perception/experience, preference, and acceptability in using doxyPEP, Cost of integrating W-DoxyPEP vs ED-DoxyPEP in routine HIV-PrEP follow-up,

—

Outcome results

None listed